Chemoprevention trials of GI cancers in Asia. Issue 6 (December 2015)

• Record Type: Journal Article
• Authors: Li, James Weiquan; Tan, Malcolm Teck Kiang; Ang, Tiing Leong; Teo, Eng Kiong
• Is Part Of: Best practice & research. Volume 29:Issue 6(2015)
• Page Start: 967
• Page End: 978
• Publication Date: 2015-12
• Subjects: Chemoprevention -- Prevention -- Risk factor -- Dysplasia -- Precancerous -- Gastric cancer -- Esophageal cancer -- Small bowel cancer -- Colorectal cancer -- Colon cancer -- Neoplasm; Gastroenterology -- Periodicals; Gastrointestinal system -- Diseases -- Periodicals; Gastrointestinal Diseases; Gastroenterology; Klinische geneeskunde; Gastro-enterologie; Gastroenterology; Gastrointestinal system -- Diseases; Periodicals; 616.33005
• DOI: 10.1016/j.bpg.2015.09.014
• Languages: English
• ISSNs: 1521-6918

Abstract

Abstract: Cancers are among the leading causes of morbidity and mortality worldwide, with gastrointestinal (GI) luminal cancers accounting for a large proportion of cancer incidence. Chemoprevention of GI luminal cancers is important to reduce this cancer burden. Screening for and eradication of Helicobacter pylori ( H. pylori ) in areas with high gastric cancer incidence is a safe and effective strategy to decrease the incidence of gastric cancer. Eradication of H. pylori also seems to be effective in preventing metachronous cancer development after endoscopic resection of early gastric cancer. For the average risk individual, COX inhibitors may have a role in reducing the incidence of adenoma formation as well as colorectal cancer, bearing in mind its inherent risks. There is currently insufficient evidence to recommend a chemoprevention agent against esophageal and small intestine cancer.